insulin and glp-1 agonist combination Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA)

or oral administration

For professionals in pharma, clinical research, and regulatory affairs, this space is evolving fastand full of opportunity

Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in vivo models of neurodegenerative diseases through modulating a variety of pathogenic mechanisms, including neuroinflammation, autophagy, mitochondrial dysfunction, and the abnormal phosphorylation of pathognomonic proteins

Includes PREDIMED data and EU health claim context.

Tirzepatide 15 mg led to higher discontinuation rate of study medication due to adverse events regardless of comparator, while all tirzepatide doses were safe in terms of serious adverse events and mortality

In this study we investigated the target occupancy of the dual agonist SAR425899 at the GLP1R in pancreas and GCGR in liver by Positron Emission Tomography/Computed Tomography (PET/CT)